Rydar Equities’s Inovio Pharmaceuticals INO Stock Holding History

Rydar Equities’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$96	Buy	+83	New	+$93	﹤0.01%	436

Other funds holding INO

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

LexAurum Advisors Overland Park, Kansas $893M AUM

Signature Estate & Investment Advisors Los Angeles, California $5.67B AUM 20.02% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

DRP

Decker Retirement Planning Levi, Utah $302M AUM 70.25% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Rydar Equities's INO Position: Q3 2026 in Review

Rydar Equities opened a new position in Inovio Pharmaceuticals (INO) in Q3 2026: 83 shares worth $96. The stake represents ﹤0.01% of the portfolio and ranks #436 among its holdings.

14 funds tracked by Wall St. Rank hold INO as of Q3 2026.

Rydar Equities held 83 shares of Inovio Pharmaceuticals worth $96 as of Q3 2026.
Inovio Pharmaceuticals was a new Rydar Equities position in Q3 2026.
Inovio Pharmaceuticals made up ﹤0.01% of Rydar Equities's portfolio in Q3 2026, its #436 holding.
14 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.